{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:35:20Z","timestamp":1783478120783,"version":"3.55.0"},"reference-count":27,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs), such as programmed cell death protein-1 (PD-1), programmed cell death protein-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4) monoclonal antibodies, are approved for the treatment of some types of advanced cancer. Their main treatment-related side-effects are immune-related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. Hypoparathyroidism, on the contrary, is an extremely rare irAE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of the study was to investigate the etiology of autoimmune hypoparathyroidism in a lung cancer patient treated with pembrolizumab, an anti-PD-1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Calcium-sensing receptor (CaSR) autoantibodies, their functional activity, immunoglobulin (Ig) subclasses and epitopes involved in the pathogenesis of autoimmune hypoparathyroidism were tested.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The patient developed hypocalcemia after 15 cycles of pembrolizumab. Calcium levels normalized with oral calcium carbonate and calcitriol and no remission of hypocalcemia was demonstrated during a 9-month follow-up. The patient was found to be positive for CaSR-stimulating antibodies, of IgG1 and IgG3 subclasses, that were able to recognize functional epitopes on the receptor, thus causing hypocalcemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The finding confirms that ICI therapy can trigger, among other endocrinopathies, hypoparathyroidism, which can be caused by pathogenic autoantibodies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa092","type":"journal-article","created":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T07:40:02Z","timestamp":1582962002000},"page":"1581-1588","source":"Crossref","is-referenced-by-count":36,"title":["Activating Antibodies to The Calcium-sensing Receptor in Immunotherapy-induced Hypoparathyroidism"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-3110","authenticated-orcid":false,"given":"Isabella","family":"Lupi","sequence":"first","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Brancatella","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Cetani","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-5904","authenticated-orcid":false,"given":"Francesco","family":"Latrofa","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Helen","family":"Kemp","sequence":"additional","affiliation":[{"name":"Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"issue":"2","key":"2021122104152841500_CIT0001","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med."},{"issue":"2","key":"2021122104152841500_CIT0002","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1210\/jc.2018-01151","article-title":"Immune checkpoint inhibitor-induced hypoparathyroidism associated with calcium-sensing receptor-activating autoantibodies","volume":"104","author":"Piranavan","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122104152841500_CIT0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev."},{"issue":"2","key":"2021122104152841500_CIT0004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1210\/jc.2017-01905","article-title":"Anti-PD-L1 treatment induced central diabetes insipidus","volume":"103","author":"Zhao","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"44","key":"2021122104152841500_CIT0005","doi-asserted-by":"crossref","first-page":"22246","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"2021122104152841500_CIT0006","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/jc.2003-031054","article-title":"Activating antibodies to the calcium-sensing receptor in two patients with autoimmune hypoparathyroidism","volume":"89","author":"Kifor","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2021122104152841500_CIT0007","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1210\/jc.2009-1080","article-title":"Activating autoantibodies against the calcium-sensing receptor detected in two patients with autoimmune polyendocrine syndrome type 1","volume":"94","author":"Kemp","year":"2009","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2021122104152841500_CIT0008","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF00543989","article-title":"Case report: primary (autoimmune?) parathyroiditis","volume":"361","author":"Van de Casseye","year":"1973","journal-title":"Virchows Arch A Pathol Pathol Anat."},{"issue":"21","key":"2021122104152841500_CIT0009","doi-asserted-by":"crossref","first-page":"8366","DOI":"10.1073\/pnas.83.21.8366","article-title":"Antibodies cytotoxic to bovine parathyroid cells in autoimmune hypoparathyroidism","volume":"83","author":"Brandi","year":"1986","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"2021122104152841500_CIT0010","doi-asserted-by":"crossref","first-page":"E1820","DOI":"10.1210\/jc.2012-1328","article-title":"Presence of strong association of the major histocompatibility complex (MHC) class I allele HLA-A*26:01 with idiopathic hypoparathyroidism","volume":"97","author":"Goswami","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122104152841500_CIT0011","first-page":"167","article-title":"Presence of autoreactive, MHC class I-restricted, calcium-sensing receptor (CaSR)-specific CD8+ T cells in idiopathic hypoparathyroidism","volume":"102","author":"Mahtab","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122104152841500_CIT0012","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s40425-019-0528-x","article-title":"Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma","volume":"7","author":"Trinh","year":"2019","journal-title":"J Immunother Cancer."},{"issue":"7","key":"2021122104152841500_CIT0013","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1200\/JOP.18.00076","article-title":"Autoimmune-related primary hypoparathyroidism possibly induced by the administration of pembrolizumab: a case report","volume":"14","author":"Umeguchi","year":"2018","journal-title":"J Oncol Pract."},{"issue":"7","key":"2021122104152841500_CIT0014","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am J Emerg Med."},{"issue":"6","key":"2021122104152841500_CIT0015","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1210\/jc.2006-2466","article-title":"The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1","volume":"92","author":"Gavalas","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2021122104152841500_CIT0016","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.4049\/jimmunol.1701527","article-title":"Calcium-sensing receptor autoantibodies in patients with autoimmune polyendocrine syndrome type 1: epitopes, specificity, functional affinity, igg subclass, and effects on receptor activity","volume":"201","author":"Habibullah","year":"2018","journal-title":"J Immunol."},{"issue":"2","key":"2021122104152841500_CIT0017","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer."},{"issue":"12","key":"2021122104152841500_CIT0018","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol."},{"issue":"10","key":"2021122104152841500_CIT0019","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res."},{"issue":"3","key":"2021122104152841500_CIT0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/cei.12438","article-title":"Thyroglobulin autoantibodies switch to immunoglobulin (Ig)G1 and IgG3 subclasses and preserve their restricted epitope pattern after 131I treatment for Graves\u2019 hyperthyroidism: the activity of autoimmune disease influences subclass distribution but not epitope pattern of autoantibodies","volume":"178","author":"Latrofa","year":"2014","journal-title":"Clin Exp Immunol."},{"issue":"5","key":"2021122104152841500_CIT0021","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1111\/j.1582-4934.2007.00096.x","article-title":"Structure and function of the human calcium-sensing receptor: insights from natural and engineered mutations and allosteric modulators","volume":"11","author":"Hu","year":"2007","journal-title":"J Cell Mol Med."},{"issue":"34","key":"2021122104152841500_CIT0022","doi-asserted-by":"crossref","first-page":"32145","DOI":"10.1074\/jbc.M102977200","article-title":"Human Ca(2+) receptor extracellular domain. Analysis of function of lobe I loop deletion mutants","volume":"276","author":"Reyes-Cruz","year":"2001","journal-title":"J Biol Chem."},{"issue":"6","key":"2021122104152841500_CIT0023","first-page":"673","article-title":"The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies","volume":"19","author":"Rapoport","year":"1998","journal-title":"Endocr Rev."},{"issue":"11","key":"2021122104152841500_CIT0024","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1210\/endo.141.11.7753","article-title":"Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor\/metabotropic glutamate chimeric receptors","volume":"141","author":"Hauache","year":"2000","journal-title":"Endocrinology."},{"issue":"45","key":"2021122104152841500_CIT0025","doi-asserted-by":"crossref","first-page":"37917","DOI":"10.1074\/jbc.M506263200","article-title":"Delineating a Ca2+ binding pocket within the Venus flytrap module of the human calcium-sensing receptor","volume":"280","author":"Silve","year":"2005","journal-title":"J Biol Chem."},{"issue":"11","key":"2021122104152841500_CIT0026","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1210\/en.2010-0424","article-title":"Neutral antibodies to the TSH receptor are present in Graves\u2019 disease and regulate selective signaling cascades","volume":"151","author":"Morshed","year":"2010","journal-title":"Endocrinology."},{"key":"2021122104152841500_CIT0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2017.09.002","article-title":"Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials","volume":"119","author":"El Osta","year":"2017","journal-title":"Crit Rev Oncol Hematol."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa092\/32717458\/dgaa092.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/5\/1581\/41828867\/jcem_105_5_1581.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/105\/5\/1581\/41828867\/jcem_105_5_1581.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T04:16:01Z","timestamp":1640060161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/5\/1581\/5766692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,2,29]]},"published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa092","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,5]]},"published":{"date-parts":[[2020,2,29]]}}}